Neuro-hormonal control of food intake; basic mechanisms and clinical implications

Journal of Physiology and Pharmacology

Volumn 56, Issue SUPPL. 6, 2005, Pages 5-25

  Konturek, P C ^b   Konturek, J W ^c   Czesnikiewicz Guzik M ^a   Brzozowski, T ^a   Sito, E ^d   Konturek, S J ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Gastroenterologie   (Germany)

^d Military Clinical Hospital Krakow   (Poland)

Author keywords

Food intake; Ghrelin; H. pylori; Hypothalamus; Leptin; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; AMPHETAMINE; COCAINE; GHRELIN; GROWTH HORMONE; MELANOCORTIN; NEUROPEPTIDE Y; OREXIN A; OREXIN B;

AMYGDALOID NUCLEUS; BASAL METABOLIC RATE; BRAIN REGION; CONFERENCE PAPER; DIABETIC OBESITY; ENERGY BALANCE; ENERGY CONSUMPTION; ENERGY EXPENDITURE; ENERGY METABOLISM; FEEDBACK SYSTEM; FOOD INTAKE; GROWTH HORMONE RELEASE; HORMONE RELEASE; HUMAN; HUNGER; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIPID STORAGE; MORBID OBESITY; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; SATIETY; STOMACH EMPTYING; THALAMUS MIDLINE NUCLEUS; THERMODYNAMICS; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSITY; ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; ARCUATE NUCLEUS; BODY WEIGHT; ENERGY METABOLISM; HUMANS; HYPOTHALAMUS; OBESITY; SIGNAL TRANSDUCTION;

EID: 31044451656     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (95)

1. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001; 22 355-375.
2. World Health Organisation. Obesity. Preventing and managing the global epidemic. Geneva, WHO, 1998.
3. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
4. Druce MR, Small CK, Bloom SR. Minireview: Gut peptides regulating satiety. Endocrinology 2004; 145: 2660-2665.
5. Vettor R, Fabris R, Pagano C, Federspil G. Neuroendocrine regulation of eating behavior. J Endocrinol Invest 2002; 25: 836-854.
6. Stricker EM. Hyperphagia. N Engl J Med 1978; 798: 1010-1015.
7. Wingate DL, Ewart WR. The brain-gut axis. In: Textbook of Gastroentelogy. T Yamada, DH Alpers, C Owyang, DW Powell, FE Silverstein (Eds.) B. Lippincott Co., Philadelphia, 1981, pp.50-60.
8. Dockray GJ. Luminal sensing in the gut; an overview. J Physiol Pharmacol 2003; 54: (Suppl 4): 9-18.
9. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in control of food intake. J Physiol Pharmacol 2004; 55 (Suppl 1): 137-154.
10. Blevins JE, Schwartz MW, Baskin DG. Peptide signals regulating food intake and energy homeostasis. Can J Physiol Pharmacol 2002; 80: 396-406.
11. Bray G.A. Afferent signals regulating food intake. Proc Natur Soc 2005; 590: 373-384.
12. Kojima M, Hosoda H, Date Y, Nakazato M, Mattsuo H, Kanagawa K. Ghrelin is a growth-hormone-relasing acylated peptide from stomach. Nature 1999; 402: 656-660.
13. Rindi G, Necchi V, Savio A, et al. Characterization of gastric ghrelin cells in man and other mammals: Studies in adult and fetal tissues. Histochem Cell Biol 2002; 117: 511-519.
14. Cummings DE, Purnell JQ, Frayo RS, Schimidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
15. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone (GH) release in humans. J Clin Endocrinol Metab 2000; 85: 4908-4911.
16. Currie PJ, Mirza A, Fuld R, Park D, Vasselli JR. Ghrelin is an anorexigenic and metabolic signaling peptide in the arcuate and paraventricular nucleus. Am J Physiol 2005; 289: R353-353.
17. Nakazato M, Murakami N, Date Y, et al. A role of ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
18. Riediger T, Traebert M, Schmidt HA, Scheel C, Lutz TA, Scharrer E. Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus. Neurosci Lett 2003; 341: 151-155.
19. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Endocrinol Metab 2001; 86: 5992-5995.
20. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 2002; 8(7): 643-644.
21. DelParigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: A potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461-5464.
22. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin and ghrelin before and after weight loss induced by gastric bypass surgery in morbidity obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602.
23. Hanusch-Enserer U, Brabant G, Rodenn M. Ghrelin concentration in morbidity obese patients after adjustable gastric bending. N Engl J Med 2003; 384: 2159-2160.
24. Brzozowski T, Konturek PC, Konturek SJ, et al. Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Reg Pept 2004; 120: 39-51.
25. Konturek PC, Brzozowski T, Burnat G, et al. Ghrelin - a new gastroprotective factor for gastric mucosa. J Physiol Pharmacol 2004; 55: 325-336.
26. Edholm T, Levin F, Hellestrom PM, Schmidt PT. Ghrelin stimulates motility in small intestine through instrinsic cholinergic neurons. Reg Pept 2004; 121: 25-30.
27. 3 secretion the role of grain-gut axis. Eur J Pharmacol 2004; 499: 15-27.
28. Konturek SJ, Pepera J, Zabielski, et al. Brain-gut axis in pancreatic secretion and appetite control. J Physiol Pharmacol 2003; 54: 293-317.
29. Kirchgessner AL. Orexins in the brain-gut axis. Endocrinol Rev 2002; 23: 1-15.
30. Sakurain T, Amemiya A, Ischi M, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585.
31. Burdyga G, Lal S, Spiller D, et al. Localization of orexins-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 2003; 124: 129-139.
32. Komaki G, Matsumoto Y, Nishikarata H, et al. Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 2001; 144: 645-651.
33. Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 2002; 26: 274-276.
34. Nalund E, Schmidt PT, Hellstrom PM. Gut peptide hormones: Importance for food intake. Scand J Gastroenterol 2005; 40: 250-258.
35. Naslund E, Ehrstrom M, Ma J, Hellstrom PM, Kirchgessner AL. Localization and effects of orexins on fasting motility in the rat duodenum. Am J Physiol 2002; 282: G470-479.
36. Garlicki J, Konturek PC, Majka J, Kwiecień N, Konturek SJ. Cholecystokinin receptors and vagal nerves in control of food intake in rats. Am J Physiol 1990; 258: E40-45.
37. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. Cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-160.
38. Ballinger A, McLoughlin L, Medback S, Clark M. Cholecystokinin is a satiety hormone in humans as physiological post-prandial concentrations. Clin Sci 1995; 89: 375-381.
39. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of Cholecystokinin in humans. Gut 1995; 36: 176-179.
40. Muurahainen N, Kissileff HR, Derogatis AJ, Pi-Sunyer FX. Effects of cholecystokinin-oktapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav 1988; 44: 644-649.
41. Rehfeldt JF. Clinical endocrinology and metabolism. Cholecystokinin. Best Pract Res Clin Endocrinol Metab 2004; 18: 569-586.
42. Geiselman PJ. Control of food intake. Endocrinol Metab Clin North Am. 1996; 25: 815-829.
43. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of Cholecystokinin. Nature 1983; 302: 703-705.
44. Schwartz GJ, Whitney A, Skoglund C, Castonguay TW, Moran TH. Decreased responsiveness to dietary fat in Otsuka Long-Evans Tokushima fatty rats lacking CCK-A receptors. Am J Physiol 1999; 277: R1144-1151.
45. Zhang Y, Proenca R, Maffei, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1983; 372: 425-432.
46. Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2003; 24: 225-253.
47. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in norma - weight and obese humans. N Engl J Med 1996; 334: 292-295.
48. Mantzoros CS, Flier JS. Editorial: leptin as a therapeutic agent-trials and tribulations. J Clin Endocrinol Metab 2000; 85: 4000-4002.
49. Konturek JW, Konturek SJ, Kwiecien S, et al. Leptin in the control of gastric secretion and gut hormones in humans infected with Helicbacter pylori. Scand J Gastroenterol 2004: 36; 1148-1564.
50. Konturek SJ, Zabielski, Konturek JW, Czarnecki J. Neuroendocrinology of the pancreas: Role of brain-axis in pancreatic secretion. Eur J Pharmacol 2003; 481: 1-14.
51. Konturek PC, Konturek SJ, Brzozowski T, Hahn EG. Gastroprotection and control of food intake. J Physiol Pharmacol 1999; 1: 39-48.
52. Cummings DE, Foster KE. Ghrelin-leptin tango in body-weight regulation. Gastroenterology 2003; 124: 1532-1535.
53. Air EL, Benoit SC, Blake Smith KA, Clegg DJ, Woods SC. Acute third ventricular administration of insulin decreases food intake in two paradigms. Pharmacol Biochem Behav. 2002; 72: 423-429.
54. Morely JE, Levine AS, Grace M, Kneip J. Peptide YY (PYY), a potent orexigenic agent. Brain Res 1985; 341: 200-203.
55. Konturek SJ, Meyers CA, Kwiecien N, et al. Effect of pancreatic polypeptide and its C-terminal hexapeptide on pancreatic secretion in man and in the dog. Scand J Gastroenterol 1982; 17: 395-403.
56. Konturek SJ, Bielanski W, Kwiecien N, Konturek JW, Czarnobilski K. Immunoneutralization of circulating pancreatic polypeptide and pancreatic secretion. Pancreas 1987; 5: 536-544.
57. Thor P, Konturek JW, Konturek SJ. Pancreatic polypeptide and intestinal motility in dogs. Dig Dis Sci 1987; 32: 513-519.
58. Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003; 124: 1325-1336.
59. Katsuura G, Asakawa A, Inui A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 2002; 23: 323-329.
60. Ueno N, Inui A, Iwamoto M, et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 1999; 117: 1427-1432.
61. Batterham RL, LeRoux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992.
62. Hilsted J, Galbo H, Sonne B, Schwartz T, et al. Gastroenteropancreatic hormonal changes during exercise. Am J Physiol 1980; 239: G136-140.
63. Berntson GG, Zipf WB, O'Dorisio TM, Hoffman JA, Chance RE. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 1993; 14: 497-503.
64. Hagan MM. Peptide YY: A key mediator or orexigenic behaviour. Peptides 2002; 23: 377-382.
65. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948.
66. Adrian TE, Ferri GL, Bacerese-Hamilton AJ, Fuessl HS, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-1077.
67. Pappas TN, Debas HT, Taylor IL. Peptide YY: metabolism and effect on pancreatic secretion in dogs. Gastroenterology 1985; 89: 1387-1394.
68. Konturek SJ, Bilski J, Pawlik W, Tasler J, Domschke W. Adrenergic pathway in the inhibition of pancreatic secretion by peptide YY in dogs. Gastroenterology 1988; 94: 266-273.
69. Hagan MM. Peptide YY: a key mediator of orexigenic behavior. Peptides 2002; 23: 377-382.
70. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-947.
71. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002; 418: 650-654.
72. Batterham RL, Bloom SR. The gut hormonepeptide YY regulates appetite. Ann NY Acad Sci 2003; 994:162-168.
73. Holst JJ. Enteroglucagon. Ann Rev Physiol 1997; 59: 257-271.
74. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
75. Naslund E, Bogefors J, Skogar S, et al. Glucagon-like peptide-1 slows solid gastric emptying with inhibition of insulin, C-peptide, glucagons and peptide YY release in humans. Am J Physiol 1999; 277: R910-916.
76. Orskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 1992; 35: 701-711.
77. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibiton of gastric emptying outweighs its insulinotropic effect in healthy humans. Am J Physiol 1997; 273: E981-988.
78. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920-927.
79. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597-601.
80. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984-992.
81. Flint A, Raben A, Astrup A, Holst JJ. Glucagon like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
82. Gutzwiller JP, Goeke B, Drewe J, et al. Glucagon-like peptide: A oitent regulator of food intake in humans. Gut 1999; 44: 81-86.
83. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagons-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-1153.
84. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 in obese men. Int J Obes 1999; 23: 304-311.
85. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Holst JJ. Attenuated GLP-1 secretion and obesity. Cause or consequence. Gut 1996; 38: 916-919.
86. Naslund E, Gryback P, Backman K, et al. Small bowel gut hormones. Correlation to fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43: 945-952.
87. Drucker DJ. Minireview: the glucagons-like peptide. Endocrinology 2001; 142: 521-515.
88. Jarrousse C, Carles-Bonnet C, Niel H, et al. Inhibition of gastric acid secretion by oxyntomodulin and its 19-37 fragment in conscious rats. Am J Physiol 1993; 264: G816-823.
89. Collie NL, Zhu Z, Jordan S, Reeve JR Jr. Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology 1997; 112: 1961-1970.
90. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142: 4244-4250.
91. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701.
92. Isomoto H, Ueno H, Saenko VA, et al. Impact of helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. Am J Gastroenterol 2005; 100: 1711-1710.
93. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003; 52: 637-640.
94. Small CJ, Bloom SR. The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity. Expert Opin Ivest Drugs 2005; 14: 647-653.
95. Konturek PC, Bielanski W, Plonka M, Pawlik T, Brzozowski T, Konturek SJ. Relationship between ghrelin and Helicobacter pylori infection in Polish adult shepherds and their children. Aliment Pharmacol Therap 2005; 22 (in press).